Russell Frank Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Russell Frank Company’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$15.4M	Sell	193,507 -62,759	-24%	-$5.68M	0.03%	718
2015 Q4	$32.4M	Sell	256,266 -111,770	-30%	-$13.5M	0.06%	370
2015 Q3	$38.3M	Buy	368,036 +115,529	+46%	+$14.8M	0.07%	305
2015 Q2	$31.2M	Buy	252,507 +211,260	+512%	+$26.6M	0.05%	429
2015 Q1	$4.87M	Buy	41,247 +2,822	+7%	+$338K	0.01%	1276
2014 Q4	$4.58M	Buy	38,425 +3,492	+10%	+$393K	0.01%	1339
2014 Q3	$3.92M	Sell	34,933 -140,175	-80%	-$13.3M	0.01%	1433
2014 Q2	$16.6M	Sell	175,108 -150,957	-46%	-$10.6M	0.03%	652
2014 Q1	$21.5M	Buy	326,065 +73,035	+29%	+$5.78M	0.04%	521
2013 Q4	$20M	Sell	253,030 -62,186	-20%	-$4.33M	0.04%	540
2013 Q3	$23.9M	Sell	315,216 -39,623	-11%	-$3.15M	0.04%	483
2013 Q2	$28.3M	Buy	+354,839	New	+$26.1M	0.05%	415

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Russell Frank Company's VRTX Position: Q1 2016 in Review

Russell Frank Company reduced its Vertex Pharmaceuticals (VRTX) stake by 24% in Q1 2016, selling an estimated $5.68M and leaving 193,507 shares worth $15.4M. The position accounts for 0.03% of the portfolio, ranked #718.

Russell Frank Company first reported a position in VRTX in Q2 2013 and has held it in 12 quarters since. The position peaked at $38.3M in Q3 2015. 503 funds tracked by Wall St. Rank hold VRTX as of Q1 2016.

Russell Frank Company held 193,507 shares of Vertex Pharmaceuticals worth $15.4M as of Q1 2016.
Russell Frank Company sold 62,759 Vertex Pharmaceuticals shares in Q1 2016, an estimated $5.68M.
Vertex Pharmaceuticals made up 0.03% of Russell Frank Company's portfolio in Q1 2016, its #718 holding.
Russell Frank Company first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 12 quarters since.
Russell Frank Company's Vertex Pharmaceuticals position peaked at $38.3M in Q3 2015.
503 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.